Q3 FY2026 · ended Sep 30, 2026 · Revenue $209.31M, +10.9% YoY · Filed Oct 30, 2026
Repligen Corp (RGEN) files with the SEC under industry code 2836, Biological Products, (No Diagnostic Substances). In Q3 of fiscal 2026, the quarter ended Sep 30, 2026, it reported revenue of $209.3 million and a net loss of $38.4 million. Free cash flow was $38.2 million. As of Sep 30, 2026 it held $863.0 million in cash and investments and $692.2 million in total debt.
Company profile
- Industry
- Biological Products, (No Diagnostic Substances) (SIC 2836)
- Listed as
- RGEN (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Waltham, MA
- SEC filer status
- Large accelerated filer
- SEC CIK
- 730272
Other Biological Products, (No Diagnostic Substances) companies
- Amgen Inc AMGN
- Gilead Sciences, Inc. GILD
- Moderna, Inc. MRNA
- Argenx SE ARGX
- Revolution Medicines, Inc. RVMD
- Biogen Inc. BIIB
- BioNTech SE BNTX
- Exelixis, Inc. EXEL
All 182 Biological Products, (No Diagnostic Substances) companies
Key figures
Fiscal-year totals from the annual reports; switch to Annual for the full-year view. Balance sheet lines are as of each year end.
| Line | Q3 FY2026 Sep 30, 2026 |
Q2 FY2026 Jun 30, 2026 |
Q1 FY2026 Mar 31, 2026 |
Q4 FY2025 Dec 31, 2025 |
Q3 FY2025 Sep 30, 2025 |
|---|---|---|---|---|---|
| Revenue | $209.3M | $204.1M | $194.3M | $197.9M | $188.8M |
| Operating income | -$29.5M | $14.0M | $15.9M | $17.9M | $16.8M |
| Net income | -$38.4M | $5.0M | $8.3M | $13.3M | $14.9M |
| Diluted EPS | -$0.68 | $0.09 | $0.15 | -$0.08 | $0.26 |
| Operating cash flow | $43.1M | $32.8M | $28.3M | $25.7M | $48.1M |
| Free cash flow | $38.2M | $27.4M | $23.6M | $17.6M | $43.4M |
| Total assets | $2.9B | $3.0B | $2.9B | $2.9B | $2.9B |
| Total liabilities | $834.7M | $838.1M | $825.3M | $843.6M | $840.6M |
| Stockholders' equity | $2.1B | $2.1B | $2.1B | $2.1B | $2.1B |
| Cash and investments | $863.0M | $810.4M | $784.5M | $767.6M | $748.7M |
| Total debt | $692.2M | $690.9M | $687.6M | $689.9M | $688.9M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 10-Q | Quarterly report | Oct 30, 2026 | Sep 30, 2026 |
| 8-K |
Current report
Unregistered share sale, Other events
|
Oct 30, 2026 | Oct 29, 2026 |
| 8-K |
Current report
Results of operations
|
Oct 27, 2026 | Oct 27, 2026 |
| 8-K |
Current report
Acquisition or sale of assets, Regulation FD disclosure
|
Oct 6, 2026 | Oct 6, 2026 |
| 8-K |
Current report
Officer or director change
|
Sep 15, 2026 | Sep 10, 2026 |
| 8-K |
Current report
Other events
|
Sep 8, 2026 | Sep 3, 2026 |
All 1003 Repligen Corp SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.